Muhammad Ahmed, MD
Psychiatry · Snellville, GANPI 1043302037
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $832 of the $944 with a category attached, or 88.2%. 9 manufacturers reported payments, led by AbbVie at 29.2% of the total. Reporting peaked in 2023 at $571 and has fallen 93.0% since, to $40 in 2025.
Across 53 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$275
- Teva Pharmaceuticals USA, Inc.$194
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$135
- Otsuka America Pharmaceutical, Inc.$133
- Neurocrine Biosciences, Inc.$106
- Johnson & Johnson$36
- plus $65 from 3 others
Across 6 payments — averaging $3724.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$22K
What the payments were for
- Food & beverage$83288%
- Education$11112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $275 |
| Teva Pharmaceuticals USA, Inc. | 7 | $194 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $135 |
| Otsuka America Pharmaceutical, Inc. | 5 | $133 |
| Neurocrine Biosciences, Inc. | 4 | $106 |
| Johnson & Johnson | 2 | $36 |
| Eisai Inc. | 1 | $29 |
| Alkermes, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$944 in reported general payments places this provider in the 65th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $169,830 |
| AustedoDeutetrabenazine | 19 | $169,101 |
| VraylarCariprazine Hcl | 52 | $78,017 |
| RexultiBrexpiprazole | 38 | $65,251 |
| Aripiprazole | 259 | $22,224 |
| CaplytaLumateperone Tosylate | 11 | $17,451 |
| BelsomraSuvorexant | 17 | $7,359 |
| Quetiapine Fumarate | 455 | $6,146 |
| Trazodone Hcl | 373 | $5,273 |
| Oxcarbazepine | 120 | $5,113 |
| Ziprasidone Hcl | 34 | $4,429 |
| Divalproex Sodium ErDivalproex Sodium | 71 | $4,354 |
| Duloxetine Hcl | 231 | $4,070 |
| Olanzapine | 103 | $4,002 |
| Paliperidone ErPaliperidone | 12 | $3,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $106 | $169,83019 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $194 | $169,10119 claims |
| AbbVieVraylar | $275 | $78,01752 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $133 | $65,25138 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $135 | $17,45111 claims |
| Eisai Inc.Dayvigo | $29 | $3,80712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Snellville
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
- Michael BurkeAtlanta$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.